What happened with GMED today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Globus Medical supplies products that surgeons use to treat spine and other musculoskeletal disorders. Its Musculoskeletal Solutions business generates most of its revenue and includes implants, related surgical supplies and spinal cord stimulation therapy. Hospitals are the main buyers of implants and disposables, paying for items used during procedures. Globus places implant and instrument sets with sales representatives or hospitals, generally without a separate charge for the instruments, and replenishes supplies after surgery. The United States is its main market.
It also sells and leases imaging, navigation and robotic equipment in its Excelsius ecosystem, including ExcelsiusGPS, which guides surgeons during implant placement. Through NuVasive Clinical Services, it monitors nerve function during spine and brain-related operations, with staff onsite and physicians interpreting data remotely. It bills Medicare and commercial insurers directly for these monitoring services; laws restricting out-of-network charges limit what it can collect.
Sales depend on surgeons choosing its products, hospitals purchasing them and insurers covering the procedures and product costs. Its direct representatives and exclusive distributors support surgeons and supply surgeries; some distributors account for a significant share of sales. Hospital purchasing approvals can make equipment sales slow and uneven. Device sales and changes to products are subject to applicable regulatory clearance or approval requirements, and the company may not promote unapproved uses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Globus’s results hinge on spine procedure volumes and surgeons’ adoption of its implants and surgical technologies, with privately held VB Spine an important rival to watch outside this list.
Alphatec competes with Globus to get spine surgeons to use its implants, procedure systems and biologics. Watch adoption of Alphatec’s approach-specific procedures: the company identifies this as a driver of future growth.
Medtronic competes directly with Globus for hospitals’ and surgeons’ purchases of spinal implants; its competing implant launches are the news most relevant to this tie.
Orthofix competes with Globus to sell spine surgeons and hospitals implants, biologics and technologies that assist surgery. Its Global Spine sales are the relevant line to watch, accounting for 84% of total net sales in 2025.
SI-BONE competes with Globus for spine and orthopedic surgeons’ use of sacroiliac fusion and pelvic fixation products. Adoption of its iFuse implants is a concrete measure to watch in this narrower surgical market.
Johnson & Johnson’s DePuy businesses compete with Globus in spinal implants and other orthopedic surgical products. DePuy product launches, rather than Johnson & Johnson’s prescription-drug results, are the news relevant to this competition.
Carlsmed challenges Globus’s spinal implants with personalized implants placed between vertebrae for spinal fusion, sold to hospitals and ambulatory surgical centers. Watch the number of surgeons using aprevo and how often they use it: Carlsmed attributes revenue growth primarily to both.
Xtant competes with Globus in biologic materials and implant systems used to fix the spine during fusion surgery, reaching hospitals through sales agents and distributors. Its spinal fixation business is more directly relevant to Globus than biologics sold for wound care or other non-spine uses.
Stryker competes with Globus to sell orthopedic implants and surgical technologies to hospitals and orthopedic surgeons. Watch its Orthopaedics sales rather than total sales, which also include its larger MedSurg and Neurotechnology business.
Zimmer Biomet competes with Globus in products for orthopedic reconstruction, trauma implants and robot-assisted surgery. Its new implants and robotic technologies are the developments to watch for this competition.
Boston Scientific competes with Globus in pain treatment: its spinal cord stimulation systems rival the Nevro products now sold by Globus.
Smith+Nephew competes with Globus to sell orthopedic implants and digital and robotic surgical technologies to healthcare customers. Its launches in these products are more relevant to Globus than its broad regional revenue totals.
GLOBUS MEDICAL INC earningsThis company
Globus Medical’s report will show whether hospitals and surgeons are buying more of its musculoskeletal products fast enough to offset the rising cost of selling and supporting them.
Compare Musculoskeletal Solutions sales with cost of sales and selling, general and administrative expense as shares of revenue. Faster sales growth with those cost shares falling would show that product adoption is translating into more efficient growth; slower sales or rising cost shares would show that growth is covering the cost of selling and supporting the business less effectively.
